Comparison of PLA microparticles and alum as adjuvants for H5N1 influenza split vaccine: Adjuvanticity evaluation and preliminary action mode analysis

Pharmaceutical Research

Volumn 31, Issue 4, 2014, Pages 1015-1031

  Zhang, Weifeng ^a,b   Wang, Lianyan ^a   Liu, Yuan ^a,b   Chen, Xiaoming ^a,b   Li, Jiahui ^a   Yang, Tingyuan ^a   An, Wenqi ^c   Ma, Xiaowei ^c   Pan, Ruowen ^c   Ma, Guanghui ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Hualan Biological Engineering Inc   (China)

Author keywords

adjuvanticity; alum; influenza vaccine; microparticles; mode of action

Indexed keywords

ALUMINUM POTASSIUM SULFATE; H5N1 INFLUENZA SPLIT VACCINE; IMMUNOGLOBULIN G; INFLUENZA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POLYLACTIC ACID; UNCLASSIFIED DRUG; ALUMINUM SULFATE; IMMUNOLOGICAL ADJUVANT; LACTIC ACID; MICROSPHERE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HEMAGGLUTINATION INHIBITION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA A (H5N1); INJECTION SITE INFLAMMATION; LYMPHOID ORGAN; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; COMPARATIVE STUDY; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A H5N1; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; FEMALE; HUMANS; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LACTIC ACID; MICE; MICE, INBRED BALB C; MICROSPHERES; POLYMERS; T-LYMPHOCYTES;

EID: 84897042301     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1224-z     Document Type: Article

References (53)

1. Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol. 2007;7(4):267-78.
2. Horimoto T, Kawaoka Y. Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol Med. 2006;12(11):506-14.
3. Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by toll-like receptor signalling. PLoS Pathog. 2008;4(8):e1000138.
4. Stropkovska A, Janulikova J, Vareckova E. Trends in development of the influenza vaccine with broader cross-protection. Acta Virol. 2010;54(1):7-19.
5. Brown LE, Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol. 2009;87(4):300-8.
6. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine. 2007;25(39-40):6852-62.
7. Tamura SI, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis. 2005;58(4):195-207.
8. Doherty PC, Kelso A. Toward a broadly protective influenza vaccine. J Clin Invest. 2008;118(10):3273-5.
9. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9(4):287-93.
10. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol. 2010;22(3):411-6.
11. Exley C, Siesjö P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 2010;31(3):103-9.
12. Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A. 2009;106(3):870-5.
13. Harris J, Sharp FA, Lavelle EC. The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants. Eur J Immunol. 2010;40(3):634-8.
14. Broaders KE, Cohen JA, Beaudette TT, Bachelder EM, Fréchet JMJ. Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy. Proc Natl Acad Sci U S A. 2009;106(14):5497-502.
15. Yanasarn N, Sloat BR, Cui Z. Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens. Mol Pharm. 2011;8(4):11741185.
16. Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine. 2007;25(11):2085-94.
17. Wei Q, Wei W, Lai B, Wang L-Y, Wang Y-x, Su Z-G, et al. Uniform-sized PLA nanoparticles: preparation by premix membrane emulsification. Int J Pharm. 2008;359(1-2):294-7.
18. Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, et al. N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine. 2007;25(1):144-53.
19. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One. 2008;3(1):e1501.
20. Hagenaars N, Mastrobattista E, Verheul R, Mooren I, Glansbeek H, Heldens J, et al. Physicochemical and immunological characterization of N, N, N-Trimethyl Chitosan-coated whole inactivated influenza virus vaccine for intranasal administration. Pharmaceut Res. 2009;26(6):1353-64.
21. Chesko J, Kazzaz J, Ugozzoli M, O'Hagan DT, Singh M. An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles. J Pharm Sci. 2005;94(11):2510-9.
22. Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Micro. 2005;3(8):591-600.
23. Ma Y, Zhuang Y, Xie X, Wang C, Wang F, Zhou D, et al. The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Nanoscale. 2011;3(5):2307-14.
24. Marzio R, Mauël J, Betz-Corradin S. CD69 and regulation of the immune function. Immunopharm Immunot. 1999;21(3):565-82.
25. Nygaard UC, Ormstad H, Aase A, Løvik M. The IgE adjuvant effect of particles: characterisation of the primary cellular response in the draining lymph node. Toxicology. 2005;206(2):181-93.
26. Lindsey W, Lowdell M, Marti G, Abbasi F, Zenger V, King K, et al. CD69 expression as an index of T-cell function: assay standardization, validation and use in monitoring immune recovery. Cytotherapy. 2007;9(2):123-32.
27. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2(4):251-62.
28. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4(3):225-34.
29. Thakur A, Pedersen LE, Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine. 2012;30(33):4907-20.
30. Patel A, Zhang Y, Croyle M, Tran K, Gray M, Strong J, et al. Mucosal delivery of adenovirus-based vaccine protects against ebola virus infection in mice. J Infect Dis. 2007;196(2):S413-20.
31. Trimnell A, Takagi A, Gupta M, Richie TL, Kappe SH, Wang R. Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of plasmodium yoelii liver stage-infected hepatocytes. J Immunol. 2009;183(9):5870-8.
32. Yue H, Wei W, Fan B, Yue Z, Wang L, Ma G, et al. The orchestration of cellular and humoral responses is facilitated by divergent intracellular antigen trafficking in nanoparticle-based therapeutic vaccine. Pharmacol Res. 2012;65(2):189-97.
33. Singh M, Chakrapani A, O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines. 2007;6(5):797-808.
34. Han RL, Zhu JM, Yang XL, Xu HB. Surface modification of poly(D, L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells. J Biomed Mater Res Part A. 2011;96A(1):142-9.
35. Klimovich V. IgM and its receptors: structural and functional aspects. Biochem Mosc. 2011;76(5):534-49.
36. Saini V, Jain V, Sudheesh MS, Jaganathan KS, Murthy PK, Kohli DV. Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen. Int J Pharm. 2011;408(1-2):50-7.
37. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science. 2005;310(5753):1510-2.
38. Woof JM. Tipping the scales toward more effective antibodies. Science. 2005;310(5753):1442-3.
39. Zhang S, Cubas R, Li M, Chen C, Yao Q. Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells. Mol Immunol. 2009;46(10):1988-2001.
40. Nimmerjahn F, Ravetch JV. Fcγ receptors: old friends and new family members. Immunity. 2006;24(1):19-28.
41. Bian G, Cheng Y, Wang Z, Hu Y, Zhang X, Wu M, et al. Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses. Vaccine. 2009;28(1):187-94.
42. Kanchan V, Panda AK. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials. 2007;28(35):5344-57.
43. Chen X, Kim P, Farinelli B, Doukas A, Yun S-H, Gelfand JA, et al. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS One. 2010;5(10):e13776.
44. Singh M, O'Hagan DT. Recent advances in vaccine adjuvants. Pharmaceut Res. 2002;19(6):715-28.
45. Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev Vaccines. 2003;2(2):269-83.
46. Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine. 2009;27(25-26):3331-4.
47. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine. 2011;29(9):1812-23.
48. Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release. 2010;147(3):342-9.
49. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006;117(1):78-88.
50. PANYAM J, W-Z ZHOU, PRABHA S, SAHOO SK, LABHASETWAR V. Rapid endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16(10):1217-26.
51. De Koker S, Lambrecht BN, Willart MA, van Kooyk Y, Grooten J, Vervaet C, et al. Designing polymeric particles for antigen delivery. Chem Soc Rev. 2011;40(1):320-39.
52. Zhou S, Liao X, Li X, Deng X, Li H. Poly-d, l-lactide-co-poly(ethylene glycol) microspheres as potential vaccine delivery systems. J Control Release. 2003;86(2-3):195-205.
53. Huntimer L, Ramer-Tait AE, Petersen LK, Ross KA, Walz KA, Wang C, et al. Evaluation of biocompatibility and administration site reactogenicity of polyanhydride-particle-based platform for vaccine delivery. Adv Healthc Mater. 2013;2(2):369-78.